

# Elizabeth Stankevich

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6965996/publications.pdf>

Version: 2024-02-01

4  
papers

1,102  
citations

1937685

4  
h-index

2272923

4  
g-index

4  
all docs

4  
docs citations

4  
times ranked

1925  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort. <i>Lung Cancer</i> , 2021, 155, 151-155.	2.0	9
2	PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer. <i>Gynecologic Oncology</i> , 2020, 159, 322-328.	1.4	51
3	First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies. <i>Clinical Cancer Research</i> , 2020, 26, 1025-1033.	7.0	45
4	PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018, 379, 341-351.	27.0	997